{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T21:14:39Z","timestamp":1771190079255,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Felllowship program","award":["2018"],"award-info":[{"award-number":["2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: We aimed to evaluate the factors associated with a virological response in a cohort of Hepatitis C virus (HCV)-infected people who inject drugs (PWID) treated with direct acting antivirals (DAAs). Methods: We conducted a multicenter retrospective cohort study enrolling HCV-infected PWID treated with DAAs. The primary outcome evaluated was the sustained virological response (SVR12) rate. Results: Five hundred and twenty HCV-infected PWID treated with all-oral DAA-based regimens were enrolled; a total of 168 (32.3%) patients presented genotype 1a, 109 (21.0%) genotype 1b, and 174 (33.5%) genotype 3; a total 152 of the 520 subjects (29.2%) were cirrhotics; a total 118 (22.7%) and 373 (71.7%) were treated with DAA regimens of second and third generation, respectively; a total 169 (33.6%) patients were receiving an opioid agonist at the start of antiviral therapy. Only 11 subjects (2.1%) did not show an SVR12. A significant correlation was found between treatment with opioid substitution therapy (p &lt; 0.001), Human Immunodeficiency Virus (HIV) coinfection (p = 0.002), and treatment with first- or second-generation regimens (p = 0.0015) and HCV failure. Upon multivariate analysis, treatment with a first- or second-generation DAA was the only factor independently associated with failure (OR 10.4, 95% CI: 1.43 to 76.1, p = 0.02). Conclusions: Treatment with DAAs led to a high SVR12 rate (97.9%) in a large cohort of HCV-infected PWID. The only predictor of viral failure found in our analysis was treatment with first- and second-generation DAA.<\/jats:p>","DOI":"10.3390\/life11010017","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T09:35:23Z","timestamp":1609320923000},"page":"17","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1323-5127","authenticated-orcid":false,"given":"Vincenzo","family":"Messina","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, AORN Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Onorato","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, AORN Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Caprio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, AORN Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Claar","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Evangelical Hospital Betania, 80147 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Iovinella","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, San Paolo Hospital, ASL Napoli 1 Centro, 80145 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-5343","authenticated-orcid":false,"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, AORN Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"},{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Rosato","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Evangelical Hospital Betania, 80147 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Salzillo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, AORN Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3320-3878","authenticated-orcid":false,"given":"Riccardo","family":"Nevola","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Evangelical Hospital Betania, 80147 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Simeone","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, AORN Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Curcio","sequence":"additional","affiliation":[{"name":"UOC Dipendenze Ovest, ASL Napoli 1 Centro, 80145 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariantonietta","family":"Pisaturo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, AORN Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"},{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4949","authenticated-orcid":false,"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, AORN Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"},{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2017). Global Hepatitis Report 2017, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cousien, A., Tran, V.C., Deuffic-Burban, S., Jauffret-Roustide, M., Dhersin, J.S., and Yazdanpanah, Y. (2016). Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology.","DOI":"10.1002\/hep.28227"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","article-title":"Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe","volume":"68","author":"Fraser","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2018.09.030","article-title":"Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia","volume":"70","author":"Iversen","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999\u20132011","volume":"21","author":"Iversen","year":"2013","journal-title":"J. Viral Hepat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"Lalezari","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir\u2013Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy","volume":"165","author":"Dore","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: A systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst. Use Misuse"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/jmv.25022","article-title":"Virological patterns of HCV patients with failure to interferon-free regimens","volume":"90","author":"Starace","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3851\/IMP3228","article-title":"HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era","volume":"23","author":"Minichini","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/liv.14170","article-title":"Real-life glecaprevir\/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study","volume":"39","author":"Persico","year":"2019","journal-title":"Liver Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"67","author":"Chung","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","unstructured":"World Health Organization (2016). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021, Pan American Health Organization. Global Hepatitis Programme, Department of the HIV\/AIDS."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jvh.13375","article-title":"Innovative procedures for micro-elimination of HCV infection in persons who use drugs","volume":"27","author":"Messina","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"2Barua, S., Greenwald, R., Grebely, J., Dore, G.J., Swan, T., and Taylor, L.E. (2015). Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann. Intern. Med., 163, 215\u2013223.","DOI":"10.7326\/M15-0406"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe","volume":"3","author":"Marshall","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/cid\/ciz1089","article-title":"Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy","volume":"71","author":"Cunningham","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugpo.2018.10.004","article-title":"Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy","volume":"62","author":"Grebely","year":"2018","journal-title":"Int. J. Drug Policy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.drugpo.2018.10.003","article-title":"Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment","volume":"62","author":"Scherz","year":"2018","journal-title":"Int. J. Drug Policy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.02.018","article-title":"Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy","volume":"71","author":"Morano","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrgastro.2015.53","article-title":"Treatment of hepatitis C in difficult-to-treat patients","volume":"12","author":"Ferenci","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1\u20136 receiving opioid substitution therapy","volume":"66","author":"Grebely","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Grebely, J., Puoti, M., Wedemeyer, H., Cooper, C., Sulkowski, M.S., Foster, G.R., Berg, T., Villa, E., Rodriguez-Perez, F., and Wyles, D.L. (2018). Efficacy and Safety of Ombitasvir\/Paritaprevir\/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infect. Dis., 5.","DOI":"10.1093\/ofid\/ofy248"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/add.14128","article-title":"Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?","volume":"113","author":"Christensen","year":"2018","journal-title":"Addiction"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/1\/17\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:00Z","timestamp":1760179680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/1\/17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["life11010017"],"URL":"https:\/\/doi.org\/10.3390\/life11010017","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]}}}